挽救性Retzius保留与标准机器人前列腺切除术的结局比较:国际多术者系列
这项国际多中心回顾性研究比较了挽救性Retzius保留机器人辅助根治性前列腺切除术(SRS-RARP)与挽救性标准机器人辅助根治性前列腺切除术(SS-RARP)的结局。共纳入9个中心72例患者(SRS-RARP 40例 vs SS-RARP 32例)。SRS-RARP在控尿功能方面显著优于SS-RARP,并发症率和肿瘤学结局无差异。
要点
- SRS-RARP控尿率显著更高:0-1个尿垫78.4% vs 43.8%,0个尿垫54.1% vs 6.3%。
- SRS-RARP每日尿垫数更少(0.57 vs 2.03),恢复控尿时间更短(中位47 vs 180天)。
- 两组并发症率和肿瘤学结局无差异,SRS-RARP是可行的挽救性选择。
核心结论
- SRS-RARP是可行的挽救性选择,显著改善排尿功能结局,可能值得增加应用。
研究设计与样本
- 国际多中心回顾性比较研究,9个中心共72例患者(SRS-RARP 40例 vs SS-RARP 32例)。
主要发现
- SRS-RARP中位随访23个月,SS-RARP中位随访36个月。
- SRS-RARP控制台时间和估计失血量优于SS-RARP。
- 两组并发症率和肿瘤学结局无差异。
- SRS-RARP控尿率更高:0-1个尿垫78.4% vs 43.8%(p<0.001),0个尿垫54.1% vs 6.3%(p<0.001)。
- SRS-RARP每日尿垫数更少(0.57 vs 2.03,p<0.001),恢复控尿时间更短(中位47 vs 180天,p=0.008)。
关键数值与推荐
- SRS-RARP与失禁风险降低相关(定义为>0-1个尿垫:HR 0.28,95%CI 0.10-0.79,p=0.016)。
- 定义为>0个尿垫时,失禁风险降低未达统计学意义(HR 0.56,95%CI 0.31-1.01,p=0.053)。
- 调整分析中SRS-RARP与每日尿垫数减少相关。
- 淋巴结清扫和以立体定向体部放疗为主要治疗与更长的控制台时间相关。
临床怎么用
- 对于非手术 primary treatment 失败的前列腺癌患者,SRS-RARP可作为挽救性选择以改善排尿功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Salvage radical prostatectomy is rare due to the risk of postoperative complications. We compare salvage Retzius-sparing robotic assisted radical prostatectomy (SRS-RARP) with salvage standard robotic assisted radical prostatectomy (SS-RARP). MATERIALS AND METHODS: A total of 72 patients across 9 centers were identified (40 SRS-RARP vs 32 SS-RARP). Demographics, perioperative data, and pathological and functional outcomes were compared using Student's t-test and ANOVA. Cox proportional hazard models and Kaplan-Meier curves were constructed to assess risk of incontinence and time to continence. Linear regression models were constructed to investigate postoperative pad use and console time. RESULTS: Median followup was 23 vs 36 months for SRS-RARP vs SS-RARP. Console time and estimated blood loss favored SRS-RARP. There were no differences in complication rates or oncologic outcomes. SRS-RARP had improved continence (78.4% vs 43.8%, p <0.001 for 0-1 pad, 54.1% vs 6.3%, p <0.001 for 0 pad), lower pads per day (0.57 vs 2.03, p <0.001), and earlier return to continence (median 47 vs 180 days, p=0.008). SRS-RARP was associated with decreased incontinence defined as >0-1 pad (HR 0.28, 95% CI 0.10-0.79, p=0.016), although not when defined as >0 pad (HR 0.56, 95% CI 0.31-1.01, p=0.053). On adjusted analysis SRS-RARP was associated with decreased pads per day. Lymph node dissection and primary treatment with stereotactic body radiation therapy were associated with longer console time. CONCLUSIONS: SRS-RARP is a feasible salvage option with significantly improved urinary function outcomes. This may warrant increased utilization of SRS-RARP to manage men who fail nonsurgical primary treatment for prostate cancer.
引用
- Kowalczyk KJ, Madi RH, Eden CG, et al. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. J Urol. 2021. PMID: 34181471. doi:10.1097/JU.0000000000001939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。